Flow cytometric quantification of intraperitoneal free tumor cells in patients with peritoneal metastasis

Cytometry Part B - Clinical Cytometry

Volumn 86, Issue 1, 2014, Pages 56-62

  Kitayama, Joji ^a   Emoto, Shigenobu ^a   Yamaguchi, Hironori ^a   Ishigami, Hironori ^a   Kamei, Takao ^a   Yamashita, Hiroharu ^a   Seto, Yasuyuki ^a   Matsuzaki, Keisuke ^b   Watanabe, Toshiaki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b Kaname cho Hospital   (Japan)

Author keywords

CD326; flowcytometry; intraperitoneal free tumor cell; peritoneal cytology; peritoneal metastasis

Indexed keywords

ANTINEOPLASTIC AGENT;

ABDOMINAL SURGERY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTRAPERITONEAL FREE TUMOR CELL; LAPAROTOMY; LEUKOCYTE; MAJOR CLINICAL STUDY; PERITONEAL CATHETER; PERITONEAL CAVITY; PERITONEUM LAVAGE; PERITONEUM METASTASIS; PRIORITY JOURNAL; STOMACH CANCER; TUMOR CELL;

CD326; FLOWCYTOMETRY; INTRAPERITONEAL FREE TUMOR CELL; PERITONEAL CYTOLOGY; PERITONEAL METASTASIS;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD45; ANTIGENS, NEOPLASM; ASCITIC FLUID; CELL ADHESION MOLECULES; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LEUKOCYTES; NEOPLASTIC CELLS, CIRCULATING; PERITONEAL CAVITY; PERITONEAL LAVAGE; PERITONEAL NEOPLASMS; STOMACH NEOPLASMS;

EID: 84890572208     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.21126     Document Type: Article

References (31)

1. Koga S, Kaibara N, Iitsuka Y, Kudo H, Kimura A, Hiraoka H,. Prognostic significance of intraperitoneal free cancer cells in gastric cancer patients. J Cancer Res Clin Oncol 1984; 108: 236-238.
2. Sodek KL, Murphy KJ, Brown TJ, Ringuette MJ,. Cell-cell and cell-matrix dynamics in intraperitoneal cancer metastasis. Cancer Metastasis Rev 2012; 31: 397-414.
3. Hayes N, Wayman J, Wadehra V, Scott DJ, Raimes SA, Griffin SM,. 1999. Peritoneal cytology in the surgical evaluation of gastric carcinoma. Br J Cancer 79: 520-524.
4. Vogel P, Ruschoff J, Kummel S, Zirngibl H, Hofstadter F, Hohenberger W, Jauch KW,. Prognostic value of microscopic peritoneal dissemination: Comparison between colon and gastric cancer. Dis Colon Rectum 2000; 43: 92-100.
5. Bando E, Yonemura Y, Takeshita Y, Taniguchi K, Yasui T, Yoshimitsu Y, Fushida S, Fujimura T, Nishimura G, Miwa K,. Intraoperative lavage for cytological examination in 1,297 patients with gastric carcinoma. Am J Surg 1999; 178: 256-262.
6. Bonenkamp JJ, Songun I, Hermans J, van de Velde CJ,. Prognostic value of positive cytology findings from abdominal washings in patients with gastric cancer. Br J Surg 1996; 83: 672-674.
7. Horattas MC, Evasovich MR, Topham N,. Colorectal carcinoma and the relationship of peritoneal cytology. Am J Surg 1997; 174: 334-337; discussion 337-338.
8. Warshaw AL,. Implications of peritoneal cytology for staging of early pancreatic cancer. Am J Surg 1991; 161: 26-29; discussion 29-30.
9. Ziselman EM, Harkavy SE, Hogan M, West W, Atkinson B,. Peritoneal washing cytology. Uses and diagnostic criteria in gynecologic neoplasms. Acta Cytol 1984; 28: 105-110.
10. Konishi M, Kinoshita T, Nakagohri T, Inoue K, Oda T, Takahashi S,. Prognostic value of cytologic examination of peritoneal washings in pancreatic cancer. Arch Surg 2002; 137: 475-480.
11. Lorenzen S, Panzram B, Rosenberg R, Nekarda H, Becker K, Schenk U, Hofler H, Siewert JR, Jager D, Ott K,. Prognostic significance of free peritoneal tumor cells in the peritoneal cavity before and after neoadjuvant chemotherapy in patients with gastric carcinoma undergoing potentially curative resection. Ann Surg Oncol 2010; 17: 2733-2739.
12. Katsuragi K, Yashiro M, Sawada T, Osaka H, Ohira M, Hirakawa K,. Prognostic impact of PCR-based identification of isolated tumour cells in the peritoneal lavage fluid of gastric cancer patients who underwent a curative R0 resection. Br J Cancer 2007; 97: 550-556.
13. Kodera Y, Nakanishi H, Ito S, Yamamura Y, Kanemitsu Y, Shimizu Y, Hirai T, Yasui K, Kato T, Tatematsu M,. 2002. Quantitative detection of disseminated free cancer cells in peritoneal washes with real-time reverse transcriptase-polymerase chain reaction: A sensitive predictor of outcome for patients with gastric carcinoma. Ann Surg 235: 499-506.
14. Rossi Del Monte S, Ranieri D, Mazzetta F, Kazemi Nava A, Raffa S, Torrisi MR, Ziparo V,. Free peritoneal tumor cells detection in gastric and colorectal cancer patients. J Surg Oncol 2012; 106: 17-23.
15. Dalal KM, Woo Y, Kelly K, Galanis C, Gonen M, Fong Y, Coit DG,. Detection of micrometastases in peritoneal washings of gastric cancer patients by the reverse transcriptase polymerase chain reaction. Gastric Cancer 2008; 11: 206-213.
16. Kowalewska M, Chechlinska M, Nowak R,. Carcinoembryonic antigen and cytokeratin 20 in peritoneal cells of cancer patients: Are we aware of what we are detecting by mRNA examination? Br J Cancer 2008; 98: 512-513; author reply 514.
17. Benevolo M, Mottolese M, Cosimelli M, Tedesco M, Giannarelli D, Vasselli S, Carlini M, Garofalo A, Natali PG,. Diagnostic and prognostic value of peritoneal immunocytology in gastric cancer. J Clin Oncol 1998; 16: 3406-3411.
18. Juhl H, Stritzel M, Wroblewski A, Henne-Bruns D, Kremer B, Schmiegel W, Neumaier M, Wagener C, Schreiber HW, Kalthoff H,. Immunocytological detection of micrometastatic cells: Comparative evaluation of findings in the peritoneal cavity and the bone marrow of gastric, colorectal and pancreatic cancer patients. Int J Cancer 1994; 57: 330-335.
19. Vogel P, Ruschoff J, Kummel S, Zirngibl H, Hofstadter F, Hohenberger W, Jauch KW,. Immunocytology improves prognostic impact of peritoneal tumour cell detection compared to conventional cytology in gastric cancer. Eur J Surg Oncol 1999; 25: 515-519.
20. Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, Dirnhofer S,. Frequent EpCam protein expression in human carcinomas. Hum Pathol 2004; 35: 122-128.
21. Spizzo G, Went P, Dirnhofer S, Obrist P, Moch H, Baeuerle PA, Mueller-Holzner E, Marth C, Gastl G, Zeimet AG,. Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol 2006; 103: 483-488.
22. Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U, Kononen J, Simon R, Sauter G, Baeuerle PA,. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 2006; 94: 128-135.
23. Pai RK, West RB,. MOC-31 exhibits superior reactivity compared with Ber-EP4 in invasive lobular and ductal carcinoma of the breast: a tissue microarray study. Appl Immunohistochem Mol Morphol 2009; 17: 202-206.
24. Linke R, Klein A, Seimetz D,. Catumaxomab: clinical development and future directions. MAbs 2010; 2: 129-136.
25. Pawelek JM, Chakraborty AK,. Fusion of tumour cells with bone marrow-derived cells: A unifying explanation for metastasis. Nat Rev Cancer 2008; 8: 377-386.
26. Spizzo G, Fong D, Wurm M, Ensinger C, Obrist P, Hofer C, Mazzoleni G, Gastl G, Went P,. EpCAM expression in primary tumour tissues and metastases: An immunohistochemical analysis. J Clin Pathol 2011; 64: 415-420.
27. Hosokawa M, Hayata T, Fukuda Y, Arakaki A, Yoshino T, Tanaka T, Matsunaga T,. Size-selective microcavity array for rapid and efficient detection of circulating tumor cells. Anal Chem 2010; 82: 6629-6635.
28. Konigsberg R, Obermayr E, Bises G, Pfeiler G, Gneist M, Wrba F, de Santis M, Zeillinger R, Hudec M, Dittrich C,. Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients. Acta Oncol 2011; 50: 700-710.
29. Mikolajczyk SD, Millar LS, Tsinberg P, Coutts SM, Zomorrodi M, Pham T, Bischoff FZ, Pircher TJ,. Detection of EpCAM-negative and cytokeratin-negative circulating tumor cells in peripheral blood. J Oncol 2011; 2011: 252361.
30. Burges A, Wimberger P, Kumper C, Gorbounova V, Sommer H, Schmalfeldt B, Pfisterer J, Lichinitser M, Makhson A, Moiseyenko V, et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: A phase I/II study. Clin Cancer Res 2007; 13: 3899-3905.
31. Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, Dudnichenko AS, Aleknaviciene B, Razbadauskas A, Gore M, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer 2010; 127: 2209-2221.